Biogen Inc.

07/26/2021 | Press release | Distributed by Public on 07/26/2021 08:04

Item-level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer’s Disease Following Treatment with High-Dose Aducanumab in the Phase 3 Study EMERGE